• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atherosclerotic Cardiovascular Risk With Combination Avelumab and Axitinib.

作者信息

Tan Sean, Day Daphne, Nicholls Stephen J, Segelov Eva

机构信息

Sean Tan, MBBS, Victorian Heart Institute, Monash University, Melbourne, Australia, Monash Heart, Monash Health, Clayton, Victoria, Australia; Daphne Day, MBBS, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Australia, Department of Oncology, Monash Health, Clayton, Victoria, Australia; Stephen J. Nicholls, MBBS, PhD, Victorian Heart Institute, Monash University, Melbourne, Australia, Monash Heart, Monash Health, Clayton, Victoria, Australia; and Eva Segelov, MBBS, PhD, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Australia, Department of Oncology, Monash Health, Clayton, Victoria, Australia.

出版信息

J Clin Oncol. 2022 Oct 10;40(29):3467-3469. doi: 10.1200/JCO.22.00712. Epub 2022 Jun 16.

DOI:10.1200/JCO.22.00712
PMID:35709408
Abstract
摘要

相似文献

1
Atherosclerotic Cardiovascular Risk With Combination Avelumab and Axitinib.阿维鲁单抗与阿昔替尼联合使用时的动脉粥样硬化性心血管风险
J Clin Oncol. 2022 Oct 10;40(29):3467-3469. doi: 10.1200/JCO.22.00712. Epub 2022 Jun 16.
2
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
3
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.avelumab 联合 axitinib 作为晚期透明细胞肾细胞癌（JAVELIN Renal 100）一线治疗的初步结果：一项开放标签、剂量发现和剂量扩展的 1b 期试验。
Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.
4
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.avelumab 联合阿昔替尼治疗老年晚期肾细胞癌的疗效和安全性：JAVELIN Renal 101 的扩展随访结果。
ESMO Open. 2022 Apr;7(2):100450. doi: 10.1016/j.esmoop.2022.100450. Epub 2022 Apr 6.
5
Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Int J Urol. 2024 Mar;31(3):273. doi: 10.1111/iju.15384. Epub 2024 Jan 3.
6
Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.模型引导药物研发支持avelumab 固定剂量方案在晚期肾细胞癌患者中的批准。
CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):458-468. doi: 10.1002/psp4.12771. Epub 2022 Feb 27.
7
Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.avelumab 联合阿昔替尼治疗肾细胞癌的安全性和有效性。
Expert Rev Anticancer Ther. 2020 May;20(5):343-354. doi: 10.1080/14737140.2020.1756780. Epub 2020 May 7.
8
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.阿昔替尼联合免疫检查点抑制剂：基于证据和专家共识的治疗优化及相关不良反应管理推荐。
Br J Cancer. 2020 Sep;123(6):898-904. doi: 10.1038/s41416-020-0949-9. Epub 2020 Jun 26.
9
Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.派姆单抗联合阿昔替尼治疗晚期肾细胞癌。
Expert Rev Anticancer Ther. 2021 Jul;21(7):693-703. doi: 10.1080/14737140.2021.1903321. Epub 2021 Apr 2.
10
[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].晚期肾细胞癌的一线治疗：一项随机、开放标签的III期研究，评估帕博利珠单抗（MK-3475）联合阿昔替尼与舒尼替尼单药治疗作为局部晚期或转移性肾细胞癌（mRCC）一线治疗的疗效和安全性（KEYNOTE-426）——AUO的AN 39/16
Urologe A. 2017 Mar;56(3):385-386. doi: 10.1007/s00120-017-0335-2.

引用本文的文献

1
Associations Between Pre-Existing Cardiovascular Disease and Survival in Patients on Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗患者中既往存在的心血管疾病与生存之间的关联。
Cancer Med. 2025 May;14(9):e70846. doi: 10.1002/cam4.70846.
2
Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: State-of-the-Art Review.肿瘤学中的免疫检查点抑制剂疗法：当前应用与未来方向：最新综述
JACC CardioOncol. 2022 Dec 20;4(5):579-597. doi: 10.1016/j.jaccao.2022.09.004. eCollection 2022 Dec.